Aaron D Schuler
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2023First federal award
$4.8MFederal grants as PI8 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
8 awards · $4.8M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Sep 17, 2026 | NIH | SBIR Phase II A Dose Expansion Study of SX-682 Alone and in Combination with Decitabine in MDS Patients | $740K | Syntrix Biosystems, Inc. |
| Sep 14, 2026 | NIH | SBIR Phase II A Phase 2 Study of SX-682 in Combination with Nivolumab and Relatlimab in Melanoma Patients | $407K | Syntrix Biosystems, Inc. |
| Jul 31, 2026 | NIH | SBIR Phase II A Phase 2, Single-Arm Study of the CXCR1/2 Inhibitor SX-682 Plus Enzalutamide in Men with Abiraterone-Resistant Metastatic Castration Resistant Prostate Cancer (mCRPC) | $576K | Syntrix Biosystems, Inc. |
| Jun 6, 2025 | NIH | SBIR Phase II A Phase 2, Single-Arm Study of the CXCR1/2 Inhibitor SX-682 Plus Enzalutamide in Men with Abiraterone-Resistant Metastatic Castration Resistant Prostate Cancer (mCRPC) | $904K | Syntrix Biosystems, Inc. |
| Apr 24, 2025 | NIH | SBIR Phase II A Dose Expansion Study of SX-682 Alone and in Combination with Decitabine in MDS Patients | $627K | Syntrix Biosystems, Inc. |
| Sep 16, 2024 | NIH | SBIR Phase II A Dose Expansion Study of SX-682 Alone and in Combination with Decitabine in MDS Patients | $400K | Syntrix Biosystems, Inc. |
| Jun 12, 2024 | NIH | SBIR Phase II A Phase 2, Single-Arm Study of the CXCR1/2 Inhibitor SX-682 Plus Enzalutamide in Men with Abiraterone-Resistant Metastatic Castration Resistant Prostate Cancer (mCRPC) | $745K | Syntrix Biosystems, Inc. |
| Jul 7, 2023 | NIH | SBIR Phase II A Phase 2, Single-Arm Study of the CXCR1/2 Inhibitor SX-682 Plus Enzalutamide in Men with Abiraterone-Resistant Metastatic Castration Resistant Prostate Cancer (mCRPC) | $400K | Syntrix Biosystems, Inc. |
Peer ranks
Federal funding#289
Awards as PI#190
Patents#273
Companies
- Syntrix Biosystems, Inc.Linked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.